NO320358B1 - Filmcoatingsammensetning, filmbelegg og modifisert frigivelsesfarmasoytisk formulering, samt fremgangsmater for fremstilling derav - Google Patents

Filmcoatingsammensetning, filmbelegg og modifisert frigivelsesfarmasoytisk formulering, samt fremgangsmater for fremstilling derav Download PDF

Info

Publication number: NO320358B1
Authority: NO; Norway
Prior art keywords: film coating; modified release; release pharmaceutical; formulation according; pharmaceutical formulation
Prior art date: 2001-12-19

Application number

NO20033653A

Other languages

English (en)

Norwegian (no)

Other versions

NO20033653D0 (no

NO20033653L (no

Inventor

Jan-Erik Lofroth

Staffan Schantz

Lars Johan Pontus De Hjartstam

Anders Welin

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-19

Filing date

2003-08-18

Publication date

2005-11-28

2001-12-19 Priority claimed from SE0104327A external-priority patent/SE0104327D0/xx

2001-12-19 Priority claimed from SE0104328A external-priority patent/SE0104328D0/xx

2003-08-18 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-08-18 Publication of NO20033653D0 publication Critical patent/NO20033653D0/no

2003-10-10 Publication of NO20033653L publication Critical patent/NO20033653L/no

2005-11-28 Publication of NO320358B1 publication Critical patent/NO320358B1/no

Links

239000007888 film coating Substances 0.000 title claims abstract description 100
238000009501 film coating Methods 0.000 title claims abstract description 100
239000000203 mixture Substances 0.000 title claims abstract description 81
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
238000000034 method Methods 0.000 title claims description 23
239000006185 dispersion Substances 0.000 claims abstract description 56
229920000642 polymer Polymers 0.000 claims abstract description 38
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims abstract description 34
229920000058 polyacrylate Polymers 0.000 claims abstract description 29
238000000576 coating method Methods 0.000 claims abstract description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
239000007788 liquid Substances 0.000 claims abstract description 23
239000011248 coating agent Substances 0.000 claims abstract description 21
239000003381 stabilizer Substances 0.000 claims description 38
238000009472 formulation Methods 0.000 claims description 35
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical group COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 28
229960002237 metoprolol Drugs 0.000 claims description 27
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 22
229920001577 copolymer Polymers 0.000 claims description 21
239000002831 pharmacologic agent Substances 0.000 claims description 21
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 16
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 16
239000000546 pharmaceutical excipient Substances 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 12
239000002245 particle Substances 0.000 claims description 12
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
229920002689 polyvinyl acetate Polymers 0.000 claims description 10
239000011118 polyvinyl acetate Substances 0.000 claims description 10
RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical group OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 claims description 9
229960000939 metoprolol succinate Drugs 0.000 claims description 9
238000002156 mixing Methods 0.000 claims description 9
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
239000004815 dispersion polymer Substances 0.000 claims description 8
239000000654 additive Substances 0.000 claims description 6
229920000847 nonoxynol Polymers 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 4
239000002876 beta blocker Substances 0.000 claims description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
150000001558 benzoic acid derivatives Chemical class 0.000 claims description 3
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
229920003163 Eudragit® NE 30 D Polymers 0.000 claims description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
230000001800 adrenalinergic effect Effects 0.000 claims description 2
229940097320 beta blocking agent Drugs 0.000 claims description 2
230000000694 effects Effects 0.000 claims description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
239000008199 coating composition Substances 0.000 claims 1
239000008188 pellet Substances 0.000 abstract description 29
-1 poly(ethyl acrylate) Polymers 0.000 description 24
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 20
239000011162 core material Substances 0.000 description 17
229940079593 drug Drugs 0.000 description 17
239000003814 drug Substances 0.000 description 17
229920003134 Eudragit® polymer Polymers 0.000 description 16
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 15
230000035699 permeability Effects 0.000 description 12
229940075507 glyceryl monostearate Drugs 0.000 description 10
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 10
239000003795 chemical substances by application Substances 0.000 description 8
239000000463 material Substances 0.000 description 8
239000004014 plasticizer Substances 0.000 description 8
238000000502 dialysis Methods 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000004816 latex Substances 0.000 description 7
229920000126 latex Polymers 0.000 description 7
239000002609 medium Substances 0.000 description 6
238000002835 absorbance Methods 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000005507 spraying Methods 0.000 description 5
239000004743 Polypropylene Substances 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000000052 comparative effect Effects 0.000 description 4
238000007906 compression Methods 0.000 description 4
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
238000001035 drying Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
239000004033 plastic Substances 0.000 description 4
229920001155 polypropylene Polymers 0.000 description 4
230000008569 process Effects 0.000 description 4
238000003756 stirring Methods 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000004809 Teflon Substances 0.000 description 3
229920006362 Teflon® Polymers 0.000 description 3
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 3
239000003833 bile salt Substances 0.000 description 3
229940093761 bile salts Drugs 0.000 description 3
230000006835 compression Effects 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000009467 reduction Effects 0.000 description 3
229940045902 sodium stearyl fumarate Drugs 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
229940033134 talc Drugs 0.000 description 3
238000012360 testing method Methods 0.000 description 3
239000001069 triethyl citrate Substances 0.000 description 3
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 3
235000013769 triethyl citrate Nutrition 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical class C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
238000013459 approach Methods 0.000 description 2
JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
238000013265 extended release Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
239000012729 immediate-release (IR) formulation Substances 0.000 description 2
238000007654 immersion Methods 0.000 description 2
239000002563 ionic surfactant Substances 0.000 description 2
229940099367 lanolin alcohols Drugs 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
239000000088 plastic resin Substances 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
239000012453 solvate Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
238000009492 tablet coating Methods 0.000 description 2
239000002700 tablet coating Substances 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
239000001993 wax Substances 0.000 description 2
CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
SSEBTPPFLLCUMN-CYBMUJFWSA-N (1r)-2-(tert-butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol Chemical compound CCC1=CC=CC2=C1OC([C@H](O)CNC(C)(C)C)=C2 SSEBTPPFLLCUMN-CYBMUJFWSA-N 0.000 description 1
NXQMNKUGGYNLBY-GFCCVEGCSA-N (2r)-1-(3-methylphenoxy)-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC(C)=C1 NXQMNKUGGYNLBY-GFCCVEGCSA-N 0.000 description 1
NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical class C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
SGUAFYQXFOLMHL-ACJLOTCBSA-N (R,R)-labetalol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(C(O)=CC=1)C(N)=O)CC1=CC=CC=C1 SGUAFYQXFOLMHL-ACJLOTCBSA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
IGFHQQFPSIBGKE-UHFFFAOYSA-N 4-nonylphenol Polymers CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
241000463291 Elga Species 0.000 description 1
YARKMNAWFIMDKV-UHFFFAOYSA-N Epanolol Chemical compound C=1C=CC=C(C#N)C=1OCC(O)CNCCNC(=O)CC1=CC=C(O)C=C1 YARKMNAWFIMDKV-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 description 1
OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
HRSANNODOVBCST-UHFFFAOYSA-N Pronethalol Chemical compound C1=CC=CC2=CC(C(O)CNC(C)C)=CC=C21 HRSANNODOVBCST-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
238000011481 absorbance measurement Methods 0.000 description 1
229960002122 acebutolol Drugs 0.000 description 1
GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
229960002213 alprenolol Drugs 0.000 description 1
PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
150000003868 ammonium compounds Chemical class 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
BHIAIPWSVYSKJS-UHFFFAOYSA-N arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 description 1
229950010731 arotinolol Drugs 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
229960004374 befunolol Drugs 0.000 description 1
ZPQPDBIHYCBNIG-UHFFFAOYSA-N befunolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960002903 benzyl benzoate Drugs 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
229960004324 betaxolol Drugs 0.000 description 1
CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
229960003588 bevantolol Drugs 0.000 description 1
HXLAFSUPPDYFEO-UHFFFAOYSA-N bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 description 1
229960002781 bisoprolol Drugs 0.000 description 1
VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
229960001035 bopindolol Drugs 0.000 description 1
CIJVBYRUFLGDHY-UHFFFAOYSA-N bucumolol Chemical compound O1C(=O)C=CC2=C1C(OCC(O)CNC(C)(C)C)=CC=C2C CIJVBYRUFLGDHY-UHFFFAOYSA-N 0.000 description 1
229950002568 bucumolol Drugs 0.000 description 1
AKLNLVOZXMQGSI-UHFFFAOYSA-N bufetolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1OCC1OCCC1 AKLNLVOZXMQGSI-UHFFFAOYSA-N 0.000 description 1
229950009385 bufetolol Drugs 0.000 description 1
229950006886 bufuralol Drugs 0.000 description 1
VCVQSRCYSKKPBA-UHFFFAOYSA-N bunitrolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1C#N VCVQSRCYSKKPBA-UHFFFAOYSA-N 0.000 description 1
229950008581 bunitrolol Drugs 0.000 description 1
NMBNQRJDEPOXCP-UHFFFAOYSA-N butofilolol Chemical compound CCCC(=O)C1=CC(F)=CC=C1OCC(O)CNC(C)(C)C NMBNQRJDEPOXCP-UHFFFAOYSA-N 0.000 description 1
229950009191 butofilolol Drugs 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
BQXQGZPYHWWCEB-UHFFFAOYSA-N carazolol Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2OCC(O)CNC(C)C BQXQGZPYHWWCEB-UHFFFAOYSA-N 0.000 description 1
229960004634 carazolol Drugs 0.000 description 1
229960001222 carteolol Drugs 0.000 description 1
LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
229960004195 carvedilol Drugs 0.000 description 1
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
229960002320 celiprolol Drugs 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
UWCBNAVPISMFJZ-UHFFFAOYSA-N cetamolol Chemical compound CNC(=O)COC1=CC=CC=C1OCC(O)CNC(C)(C)C UWCBNAVPISMFJZ-UHFFFAOYSA-N 0.000 description 1
229950003205 cetamolol Drugs 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
229960004893 cloranolol Drugs 0.000 description 1
XYCMOTOFHFTUIU-UHFFFAOYSA-N cloranolol Chemical compound CC(C)(C)NCC(O)COC1=CC(Cl)=CC=C1Cl XYCMOTOFHFTUIU-UHFFFAOYSA-N 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
238000011968 cross flow microfiltration Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000010908 decantation Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
229940031954 dibutyl sebacate Drugs 0.000 description 1
229950007942 dilevalol Drugs 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229960000878 docusate sodium Drugs 0.000 description 1
NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229960002711 epanolol Drugs 0.000 description 1
AFSIMBWBBOJPJG-UHFFFAOYSA-N ethenyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC=C AFSIMBWBBOJPJG-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000012734 extended-release (ER) formulation Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
150000002303 glucose derivatives Chemical class 0.000 description 1
229930182478 glucoside Natural products 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
150000002334 glycols Polymers 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
229950008838 indenolol Drugs 0.000 description 1
239000003999 initiator Substances 0.000 description 1
239000000976 ink Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
239000003350 kerosene Substances 0.000 description 1
229960001632 labetalol Drugs 0.000 description 1
229960000831 levobunolol Drugs 0.000 description 1
IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229960003134 mepindolol Drugs 0.000 description 1
150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
125000005395 methacrylic acid group Chemical group 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229960002704 metipranolol Drugs 0.000 description 1
BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 1
238000001471 micro-filtration Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229940042472 mineral oil Drugs 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
LFTFGCDECFPSQD-UHFFFAOYSA-N moprolol Chemical compound COC1=CC=CC=C1OCC(O)CNC(C)C LFTFGCDECFPSQD-UHFFFAOYSA-N 0.000 description 1
229950002481 moprolol Drugs 0.000 description 1
229960004255 nadolol Drugs 0.000 description 1
VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
UPZVYDSBLFNMLK-UHFFFAOYSA-N nadoxolol Chemical compound C1=CC=C2C(OCC(O)CC(/N)=N/O)=CC=CC2=C1 UPZVYDSBLFNMLK-UHFFFAOYSA-N 0.000 description 1
229960004501 nadoxolol Drugs 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229950000754 nipradilol Drugs 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Polymers CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229960004570 oxprenolol Drugs 0.000 description 1
239000003973 paint Substances 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
229960002508 pindolol Drugs 0.000 description 1
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920001004 polyvinyl nitrate Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960001749 practolol Drugs 0.000 description 1
DURULFYMVIFBIR-UHFFFAOYSA-N practolol Chemical compound CC(C)NCC(O)COC1=CC=C(NC(C)=O)C=C1 DURULFYMVIFBIR-UHFFFAOYSA-N 0.000 description 1
238000007639 printing Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
229950000992 pronetalol Drugs 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000012552 review Methods 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
235000017709 saponins Nutrition 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000000344 soap Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
OABYVIYXWMZFFJ-ZUHYDKSRSA-M sodium glycocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 OABYVIYXWMZFFJ-ZUHYDKSRSA-M 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
229960002370 sotalol Drugs 0.000 description 1
ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000004154 testing of material Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
TWVUMMQUXMYOOH-UHFFFAOYSA-N tilisolol Chemical compound C1=CC=C2C(=O)N(C)C=C(OCC(O)CNC(C)(C)C)C2=C1 TWVUMMQUXMYOOH-UHFFFAOYSA-N 0.000 description 1
229950008411 tilisolol Drugs 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
229950000245 toliprolol Drugs 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical class [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
RKUQLAPSGZJLGP-UHFFFAOYSA-N xibenolol Chemical compound CC1=CC=CC(OCC(O)CNC(C)(C)C)=C1C RKUQLAPSGZJLGP-UHFFFAOYSA-N 0.000 description 1
229950001124 xibenolol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Medicinal Preparation (AREA)
Paints Or Removers (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Piezo-Electric Transducers For Audible Bands (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Surface Treatment Of Glass Fibres Or Filaments (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compositions Of Macromolecular Compounds (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

NO20033653A 2001-12-19 2003-08-18 Filmcoatingsammensetning, filmbelegg og modifisert frigivelsesfarmasoytisk formulering, samt fremgangsmater for fremstilling derav NO320358B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE0104327A SE0104327D0 (sv)	2001-12-19	2001-12-19	New film coating
SE0104328A SE0104328D0 (sv)	2001-12-19	2001-12-19	New film coating
PCT/GB2002/005739 WO2003051340A1 (en)	2001-12-19	2002-12-18	New film coating

Publications (3)

Publication Number	Publication Date
NO20033653D0 NO20033653D0 (no)	2003-08-18
NO20033653L NO20033653L (no)	2003-10-10
NO320358B1 true NO320358B1 (no)	2005-11-28

Family

ID=26655630

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20033653A NO320358B1 (no)	2001-12-19	2003-08-18	Filmcoatingsammensetning, filmbelegg og modifisert frigivelsesfarmasoytisk formulering, samt fremgangsmater for fremstilling derav

Country Status (25)

Country	Link
US (2)	US6827947B2 (cs)
EP (2)	EP1355633B1 (cs)
JP (1)	JP2005514386A (cs)
KR (1)	KR20040065989A (cs)
CN (1)	CN100341491C (cs)
AT (1)	ATE287259T1 (cs)
AU (2)	AU2002361447B2 (cs)
BR (1)	BR0206441A (cs)
CA (1)	CA2435729C (cs)
CZ (1)	CZ20031970A3 (cs)
DE (2)	DE20220902U1 (cs)
DK (1)	DK1355633T3 (cs)
ES (1)	ES2233876T3 (cs)
HU (1)	HUP0303886A3 (cs)
IL (1)	IL156998A0 (cs)
IS (1)	IS6863A (cs)
MX (1)	MXPA03007156A (cs)
NO (1)	NO320358B1 (cs)
NZ (1)	NZ526926A (cs)
PL (1)	PL362378A1 (cs)
PT (1)	PT1355633E (cs)
RU (1)	RU2323717C2 (cs)
SI (1)	SI1355633T1 (cs)
SK (1)	SK9132003A3 (cs)
WO (1)	WO2003051340A1 (cs)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0100200D0 (sv) *	2001-01-24	2001-01-24	Astrazeneca Ab	New film coating
EP1355633B1 (en) *	2001-12-19	2005-01-19	AstraZeneca AB	NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate
CA2476201C (en)	2002-02-21	2009-09-01	Biovail Laboratories Incorporated	Modified release formulations of at least one form of tramadol
SE0201110D0 (sv) *	2002-04-12	2002-04-12	Astrazeneca Ab	New film coating
SE0202353D0 (sv) *	2002-08-01	2002-08-01	Astrazeneca Ab	New film coating
US7080545B2 (en) *	2002-10-17	2006-07-25	Advanced Technology Materials, Inc.	Apparatus and process for sensing fluoro species in semiconductor processing systems
NZ547284A (en) *	2003-10-31	2009-12-24	Hexal Ag	Pharmaceutical agent-containing formulation comprising a coating of a film forming polymer
WO2005084636A2 (en) *	2004-02-27	2005-09-15	Ranbaxy Laboratories Limited	A process for the preparation of controlled-release pharmaceutical composition of metoprolol
JP2005306778A (ja) *	2004-04-21	2005-11-04	Basf Ag	徐放性製剤及びその製造方法
US7838031B2 (en) *	2004-05-21	2010-11-23	Lawrence Solomon	Method of administering a partial dose using a segmented pharmaceutical tablet
DE102004035936A1 (de) *	2004-07-23	2006-03-16	Röhm GmbH & Co. KG	Mehrschichtige Arzneiform
US20070048371A1 (en) *	2005-07-28	2007-03-01	Shojaei Amir H	Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
US8231902B2 (en) *	2005-11-18	2012-07-31	Accu-Break Technologies, Inc.	Segmented pharmaceutical dosage forms
DE102005060393A1 (de) *	2005-12-16	2007-06-21	Add Advanced Drug Delivery Technologies Ltd.	Orales Präparat mit kontrollierter Freisetzung
US20080118570A1 (en) *	2006-11-20	2008-05-22	Zhi Liu	Polymer coated drug-ion exchange resins and methods
US20100303920A1 (en) *	2009-05-27	2010-12-02	Johan Hjartstam	Aqueous Film Coating Composition / 841
EP2461811B1 (en)	2009-08-05	2016-04-20	Idenix Pharmaceuticals LLC.	Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011056764A1 (en)	2009-11-05	2011-05-12	Ambit Biosciences Corp.	Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
KR20120118008A (ko)	2009-12-18	2012-10-25	아이데닉스 파마슈티칼스, 인코포레이티드	5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
IL210279A0 (en)	2009-12-25	2011-03-31	Dexcel Pharma Technologies Ltd	Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
WO2011094890A1 (en)	2010-02-02	2011-08-11	Argusina Inc.	Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011112689A2 (en)	2010-03-11	2011-09-15	Ambit Biosciences Corp.	Saltz of an indazolylpyrrolotriazine
ES2579942T3 (es)	2010-09-01	2016-08-17	Ambit Biosciences Corporation	Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
CN103270030B (zh)	2010-09-01	2016-01-20	埃姆比特生物科学公司	吡唑基氨基喹唑啉的氢溴酸盐
EP2648676A4 (en)	2010-12-06	2016-05-04	Follica Inc	METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
WO2012080050A1 (en)	2010-12-14	2012-06-21	F. Hoffmann-La Roche Ag	Solid forms of a phenoxybenzenesulfonyl compound
WO2012106299A1 (en)	2011-01-31	2012-08-09	Celgene Corporation	Pharmaceutical compositions of cytidine analogs and methods of use thereof
AR085352A1 (es)	2011-02-10	2013-09-25	Idenix Pharmaceuticals Inc	Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en)	2011-03-31	2012-10-04	Idenix Pharmaceuticals, Inc.	Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
BR112013027484A8 (pt) *	2011-06-17	2022-07-05	Evonik Roehm Gmbh	Composição farmacêutica ou nutracêutica com resistência gástrica, e uso de um polímero de (met)acrilato
AU2011370762A1 (en) *	2011-06-17	2013-11-14	Evonik Rohm Gmbh	Coating composition suitable for pharmaceutical or nutraceutical dosage forms
KR20140138293A (ko)	2012-03-16	2014-12-03	액시킨 파마수티컬스 인코포레이티드	3,5-다이아미노피라졸 키나아제 억제제
BR112015018895A2 (pt)	2013-02-13	2017-07-18	Evonik Roehm Gmbh	composição farmacêutica multiparticulada compreendendo uma multiplicidade de dois tipos de pelotas
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (en)	2013-09-20	2016-07-27	IDENIX Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
JP5846185B2 (ja)	2013-11-21	2016-01-20	大日本印刷株式会社	貫通電極基板及び貫通電極基板を用いた半導体装置
US20170066779A1 (en)	2014-03-05	2017-03-09	Idenix Pharmaceuticals Llc	Solid forms of a flaviviridae virus inhibitor compound and salts thereof
KR102409739B1 (ko)	2014-03-20	2022-06-17	카펠라 테라퓨틱스, 인크.	암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
KR102416358B1 (ko)	2014-03-20	2022-07-07	카펠라 테라퓨틱스, 인크.	암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
MX2017000384A (es) *	2014-07-09	2017-04-27	Sun Pharmaceutical Ind Ltd	Forma de dosificacion en capsulas de succinato de metoprolol.
WO2016042565A1 (en) *	2014-09-16	2016-03-24	Suresh Pareek	Extended release 'formulation of metoprolol
US9546163B2 (en)	2014-12-23	2017-01-17	Axikin Pharmaceuticals, Inc.	3,5-diaminopyrazole kinase inhibitors
SG11201811579VA (en) *	2016-06-30	2019-01-30	Beckman Coulter Inc	Chemiluminescent substrates
ES3040411T3 (en)	2018-03-22	2025-10-30	Incarda Therapeutics Inc	A novel method to slow ventricular rate
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB878234A (en)	1958-12-18	1961-09-27	Roehm & Haas Gmbh	Pharmaceutical coating compositions
DE1228757B (de)	1962-06-28	1966-11-17	Haessle Ab	Verfahren zur Herstellung eines in Wasser und Magensaft rasch zerfallenden UEberzuges auf festen Arzneiformen
US3341338A (en)	1965-05-28	1967-09-12	Union Carbide Corp	Polysiloxane polish formulations
DE2031871C3 (de)	1970-06-27	1974-06-27	Roehm Gmbh, 6100 Darmstadt	Überzugsmasse für Arzneiformen
US4330338A (en) *	1978-10-02	1982-05-18	Purdue Research Foundation	Pharmaceutical coating composition, and preparation and dosages so coated
US4916171A (en)	1984-07-25	1990-04-10	Rohm And Haas Company	Polymers comprising alkali-insoluble core/alkali-soluble shell and copositions thereof
SE8404467D0 (sv)	1984-09-06	1984-09-06	Ferrosan Ab	Controlled-release medical preparations
SE450087B (sv)	1985-10-11	1987-06-09	Haessle Ab	Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
SE455836B (sv)	1985-10-11	1988-08-15	Haessle Ab	Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
US5246714A (en)	1985-10-11	1993-09-21	Aktiebolaget Hassle	Drug preparation
US4975283A (en)	1985-12-12	1990-12-04	Bristol-Myers Squibb Company	Stabilized enteric coated aspirin granules and process for preparation
US4800087A (en) *	1986-11-24	1989-01-24	Mehta Atul M	Taste-masked pharmaceutical compositions
US4874613A (en) *	1987-03-06	1989-10-17	Baker Cummins Pharmaceuticals, Inc.	Taste concealing pharmaceutical dosage unit
US4871546A (en) *	1987-06-29	1989-10-03	Sandoz Pharm. Corp.	Gastrointestinal protective coating formulations
JP2782691B2 (ja) *	1987-09-29	1998-08-06	ワーナー−ランバート・コンパニー	腸溶製剤の安定化
US5292522A (en) *	1989-06-20	1994-03-08	Rohm Gmbh	Aqueous film coating agent for solid medicaments
FR2655266B1 (fr)	1989-12-05	1992-04-03	Smith Kline French Lab	Compositions pharmaceutiques a base de cimetidine.
GB9200607D0 (en)	1992-01-13	1992-03-11	Ethical Pharma Ltd	Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5376384A (en)	1992-12-23	1994-12-27	Kinaform Technology, Inc.	Delayed, sustained-release pharmaceutical preparation
ATE195252T1 (de)	1993-04-23	2000-08-15	Novartis Erfind Verwalt Gmbh	Wirkstoffabgabevorrichtung mit gesteuerter freigabe
CA2117546A1 (en) *	1993-08-27	1995-02-28	Takateru Muraoka	Medical adhesive sheet
DE4444051A1 (de)	1994-12-10	1996-06-13	Rhone Poulenc Rorer Gmbh	Pharmazeutische, oral anwendbare Zubereitung
US5871776A (en)	1995-01-31	1999-02-16	Mehta; Atul M.	Controlled-release nifedipine
DE19615812A1 (de) *	1996-04-20	1997-10-23	Boehringer Mannheim Gmbh	Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US6046177A (en)	1997-05-05	2000-04-04	Cydex, Inc.	Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US6627223B2 (en) *	2000-02-11	2003-09-30	Eurand Pharmaceuticals Ltd.	Timed pulsatile drug delivery systems
SE0100200D0 (sv)	2001-01-24	2001-01-24	Astrazeneca Ab	New film coating
EP1355633B1 (en) *	2001-12-19	2005-01-19	AstraZeneca AB	NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate
US20030175342A1 (en) *	2002-03-14	2003-09-18	Karl Kolter	Coated pharmaceutical single-unit delayed-release forms, based on polyvinyl acetate
SE0201110D0 (sv) *	2002-04-12	2002-04-12	Astrazeneca Ab	New film coating
SE0202353D0 (sv)	2002-08-01	2002-08-01	Astrazeneca Ab	New film coating

2002
- 2002-12-18 EP EP02796920A patent/EP1355633B1/en not_active Expired - Lifetime
- 2002-12-18 AT AT02796920T patent/ATE287259T1/de not_active IP Right Cessation
- 2002-12-18 NZ NZ526926A patent/NZ526926A/en unknown
- 2002-12-18 PT PT02796920T patent/PT1355633E/pt unknown
- 2002-12-18 RU RU2003125371/15A patent/RU2323717C2/ru active
- 2002-12-18 WO PCT/GB2002/005739 patent/WO2003051340A1/en not_active Ceased
- 2002-12-18 MX MXPA03007156A patent/MXPA03007156A/es active IP Right Grant
- 2002-12-18 EP EP04019487A patent/EP1477163A1/en not_active Withdrawn
- 2002-12-18 PL PL36237802A patent/PL362378A1/xx not_active Application Discontinuation
- 2002-12-18 CZ CZ20031970A patent/CZ20031970A3/cs unknown
- 2002-12-18 AU AU2002361447A patent/AU2002361447B2/en not_active Ceased
- 2002-12-18 DE DE20220902U patent/DE20220902U1/de not_active Expired - Lifetime
- 2002-12-18 CA CA002435729A patent/CA2435729C/en not_active Expired - Fee Related
- 2002-12-18 IL IL15699802A patent/IL156998A0/xx unknown
- 2002-12-18 HU HU0303886A patent/HUP0303886A3/hu unknown
- 2002-12-18 SK SK913-2003A patent/SK9132003A3/sk unknown
- 2002-12-18 SI SI200230088T patent/SI1355633T1/xx unknown
- 2002-12-18 US US10/450,794 patent/US6827947B2/en not_active Expired - Fee Related
- 2002-12-18 ES ES02796920T patent/ES2233876T3/es not_active Expired - Lifetime
- 2002-12-18 BR BR0206441-3A patent/BR0206441A/pt not_active IP Right Cessation
- 2002-12-18 KR KR10-2003-7010812A patent/KR20040065989A/ko not_active Ceased
- 2002-12-18 DE DE60202662T patent/DE60202662T2/de not_active Expired - Lifetime
- 2002-12-18 CN CNB028084683A patent/CN100341491C/zh not_active Expired - Lifetime
- 2002-12-18 JP JP2003552273A patent/JP2005514386A/ja not_active Withdrawn
- 2002-12-18 DK DK02796920T patent/DK1355633T3/da active
2003
- 2003-07-01 IS IS6863A patent/IS6863A/is unknown
- 2003-08-18 NO NO20033653A patent/NO320358B1/no not_active IP Right Cessation
2004
- 2004-09-16 US US10/942,407 patent/US7815938B2/en not_active Expired - Lifetime
2008
- 2008-08-28 AU AU2008207594A patent/AU2008207594A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE287259T1 (de)	2005-02-15
HUP0303886A2 (hu)	2004-05-28
SK9132003A3 (en)	2004-02-03
CZ20031970A3 (cs)	2003-10-15
JP2005514386A (ja)	2005-05-19
NO20033653D0 (no)	2003-08-18
PT1355633E (pt)	2005-05-31
AU2002361447A1 (en)	2003-06-30
MXPA03007156A (es)	2003-11-18
HUP0303886A3 (en)	2005-05-30
CA2435729A1 (en)	2003-06-26
AU2008207594A1 (en)	2008-09-18
EP1355633A1 (en)	2003-10-29
ES2233876T3 (es)	2005-06-16
DE20220902U1 (de)	2004-06-09
IS6863A (is)	2003-07-01
EP1355633B1 (en)	2005-01-19
RU2003125371A (ru)	2005-02-10
US20040030033A1 (en)	2004-02-12
NZ526926A (en)	2006-02-24
BR0206441A (pt)	2003-12-30
AU2002361447B2 (en)	2008-05-29
DE60202662D1 (de)	2005-02-24
CN1503663A (zh)	2004-06-09
EP1477163A1 (en)	2004-11-17
SI1355633T1 (en)	2005-06-30
IL156998A0 (en)	2004-02-08
DK1355633T3 (da)	2005-04-04
DE60202662T2 (de)	2006-01-05
US6827947B2 (en)	2004-12-07
PL362378A1 (en)	2004-10-18
US7815938B2 (en)	2010-10-19
WO2003051340A1 (en)	2003-06-26
US20050089574A1 (en)	2005-04-28
KR20040065989A (ko)	2004-07-23
CN100341491C (zh)	2007-10-10
RU2323717C2 (ru)	2008-05-10
NO20033653L (no)	2003-10-10
HK1058312A1 (en)	2004-05-14
CA2435729C (en)	2005-12-13

Legal Events

Date	Code	Title	Description
2010-07-19	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO320358B1 (no)	2005-11-28	Filmcoatingsammensetning, filmbelegg og modifisert frigivelsesfarmasoytisk formulering, samt fremgangsmater for fremstilling derav
EP1496870B1 (de)	2009-09-02	Arzneiform und verfahren zu ihrer herstellung
US3247066A (en)	1966-04-19	Controlled release dosage form containing water-swellable beadlet
EP1478352B1 (de)	2006-08-16	Arzneiform und verfahren ihrer herstellung
WO2001068058A1 (de)	2001-09-20	Mehrschichtige arzneiform für die colonfreigabe
US20030104061A1 (en)	2003-06-05	Controlled release tramadol preparations with a storage-stable release profile and process for their production
JP2018065846A (ja)	2018-04-26	哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
US20070184102A1 (en)	2007-08-09	Latex or pseudolatex compositions, coatings and coating processes
US20050238719A1 (en)	2005-10-27	Film coating
HK1058312B (en)	2005-05-27	New film coating containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate
US10653631B2 (en)	2020-05-19	Optimal colon targeting technology
UA80940C2 (en)	2007-11-26	Pharmaceutical formulation to provide modified release and a tablet containig thereof
Skalsky et al.	2016	9 Chemistry and